Prothrombin Gene Mutation (Factor II Mutation)

What the prothrombin mutation is

Prothrombin (clotting factor II) is made in the liver. When you are injured, it is converted into thrombin, the enzyme that turns fibrinogen into the fibrin mesh of a blood clot.

The G20210A change is a single letter swap in a part of the F2 gene that controls how much prothrombin is made. People with it have about 30% higher prothrombin levels. The blood still clots and stops clotting normally, but the balance is tipped slightly toward clotting, especially when other risks are added.

Heterozygous vs homozygous

The absolute risk for a heterozygous carrier remains low. The general population has roughly a 1 in 1,000 chance per year of a venous clot; carrying one copy raises that to roughly 2 to 3 in 1,000.

Clots linked to the mutation

• Deep vein thrombosis (DVT): a clot in the leg or pelvis veins, causing swelling, pain, warmth and redness of one leg
• Pulmonary embolism (PE): a clot traveling to the lungs, causing breathlessness, chest pain and sometimes collapse
• Cerebral venous thrombosis: a clot in the brain's draining veins, more strongly linked to this mutation than other inherited thrombophilias, especially with estrogen use
• Clots in unusual sites: the veins of the liver or gut

The link with arterial clots such as heart attack and stroke is weak in most people, though it may be stronger in young people with other risk factors.

Triggers that add to the risk

Most clots in carriers happen when other risks are present:

• estrogen-containing birth control (combined pill, patch, ring) and estrogen hormone therapy
• pregnancy and the 6 weeks after birth
• surgery, especially orthopedic, and immobility
• long-haul travel over about 4 hours
• cancer and its treatment
• obesity and smoking
• older age

Testing

The test is a DNA blood test for the F2 G20210A variant. Prothrombin activity levels cannot reliably detect it.

Testing is not recommended for everyone. Major guidelines suggest considering it when results would change management, for example:

• a clot without a strong trigger, especially at a young age
• clots in unusual places, such as the brain's veins
• a close family member with a known thrombophilia, when you are considering estrogen or pregnancy
• planning pregnancy with a strong family history of clots

Testing after a clot is often done when deciding how long to continue blood thinners, though for many people the circumstances of the clot matter more than the test result.

Treatment and management

Carriers who have never had a clot

• No regular medication is needed.
• Avoid estrogen-containing contraception if there is also a family history of clots or you are homozygous; progestogen-only and non-hormonal methods (IUDs, implants, progestogen pill) are safer options.
• Ask about short-term preventive blood thinners for major surgery or prolonged immobility.
• On long flights: walk around, flex your calves, and stay hydrated; compression stockings may help.

After a clot

• Anticoagulants (blood thinners) such as apixaban, rivaroxaban, low-molecular-weight heparin or warfarin are given for at least 3 months.
• Whether to continue long term depends mostly on whether the clot was provoked (by surgery, for example) or unprovoked, bleeding risk and personal preference, rather than on the mutation itself.

Pregnancy

Pregnancy raises clot risk several-fold, and the risk is highest in the weeks after birth. For carriers:

• Heterozygous, no previous clot: often monitoring only during pregnancy, and preventive heparin injections for 6 weeks after birth if there is a family history of clots.
• Homozygous, or combined with factor V Leiden: preventive heparin is often advised during pregnancy and after birth.
• Previous clot: preventive heparin during pregnancy and for 6 weeks after.

The link between this mutation and miscarriage or placental problems is weak, and routine treatment for these reasons is not recommended.

Outlook

Most people with the prothrombin mutation live normal lives and never have a clot. Knowing you carry it helps you and your doctors manage risky situations, such as choosing contraception, planning surgery and pregnancy, and recognizing clot symptoms early. Family members can choose whether to be tested; this is most useful for women considering estrogen or pregnancy.

Frequently asked questions

Is the prothrombin gene mutation serious?

For most people with one copy, no. It roughly doubles or triples the risk of a vein clot, but that risk starts low, and most carriers never have one. It matters more when combined with other risks such as estrogen, pregnancy, surgery or a second clotting mutation.

What does heterozygous prothrombin gene mutation mean?

It means you inherited one copy of the mutation from one parent and a normal copy from the other. This is the common form. It raises clot risk modestly. Being homozygous (two copies) is rare and raises the risk further.

Can I take birth control with a prothrombin mutation?

Estrogen-containing methods (combined pill, patch and ring) increase clot risk further and are usually avoided, especially with a personal or family history of clots. Progestogen-only pills, implants, hormonal IUDs and copper IUDs do not raise clot risk significantly and are generally preferred.

Do I need blood thinners if I have the prothrombin mutation?

Not usually, unless you have had a clot. Carriers without a clot normally need no daily medicine. Short-term preventive blood thinners may be advised around surgery, after childbirth or during pregnancy in higher-risk situations.

Should my family get tested?

Testing relatives is optional. It is most useful for female relatives considering estrogen contraception or pregnancy, because a result might change their choices. Discuss it with your doctor or a genetic counselor, since a positive result can cause worry without changing care.